ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Operating income 2017–2025
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) annual operating income history from SEC filings — each fiscal year as reported.
-$57.1MFY2025 · since FY2017: -$44.5M → -$57.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$57.1M | +64.9% |
| FY2024 | -$162.5M | +28.4% |
| FY2023 | -$227.0M | -13.4% |
| FY2022 | -$200.2M | +4.2% |
| FY2021 | -$209.0M | -36.7% |
| FY2020 | -$152.8M | -94.9% |
| FY2019 | -$78.4M | -57.6% |
| FY2018 | -$49.8M | -11.9% |
| FY2017 | -$44.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ADPT financial trends
ADPT RevenueADPT Net incomeADPT Net marginADPT Gross profitADPT Gross marginADPT Operating marginADPT Operating cash flowADPT Free cash flowADPT Capital expendituresADPT Return on equityADPT Stock buybacksADPT Dividends paidADPT Total assetsADPT Total liabilitiesADPT Shareholders’ equityADPT overview →